Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing
Reexamination Certificate
2003-04-04
2010-02-09
Leavitt, Maria (Department: 1633)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
C424S094600, C424S094610, C435S069100, C435S183000, C435S195000, C435S200000
Reexamination Certificate
active
07658916
ABSTRACT:
Methods of modulating uptake of extracellular lysosomal enzymes by administering a pharmaceutical agent and methods of treating a lysosomal storage disease (such as Gaucher disease, Pompe disease, Fabry disease or Niemann-Pick disease) or enhancing enzyme replacement therapy or gene therapy, comprising administering a pharmaceutical agent such as dexamethasone, glucose or insulin, are provided.
REFERENCES:
patent: 5236838 (1993-08-01), Rasmussen et al.
patent: 5401650 (1995-03-01), Desnick et al.
patent: 5879680 (1999-03-01), Ginns et al.
patent: WO 00/12740 (2000-03-01), None
patent: WO 00/34451 (2000-06-01), None
East et al., The Mannose Receptor Family, Biochimica and biophysica acta 2002, 1572:364-386.
Weiger PH, Galactosyl and N-AcetylGalactosaminyl Homeotastsis:A Funtion for Mammalian Asialoglycoprotein Receptor. BiEssays, 1994, 16:519-524.
Rusittu el al., Modulation of cell surface expression of liver carbohydrate receptors during in vivo induction of apoptosis with lead nitrate. Cell Tissue Res, 1999, 298: 105-112.
Devirgiliis L Conti , Bruscalupi G, Dini L, Modulation of asialoglycoprotein binding activity in livers of pregnant or estrogen-treated rats. Biosci Rep. 1989 9:701-7.
Doyle AG, Herbein G, Montaner LJ, Minty AJ, Caput D, Ferrara P, Gordon S. Interleukin-13 alters the activation state of murine macrophages in vitro: comparison with interleukin-4 and interferon-gamma. Eur J lmmunol. 1994 ;24:1441-5.
Stockert RJ, Morell AG.Second messenger modulation of the asialoglycoprotein receptor. J Biol Chem. 1990 265:1841-6.
Weiss P, Ashwell G.The asialoglycoprotein receptor: properties and modulation by ligand. Prog Clin Biol Res. 1989;300:169-84.
Weiss P, Ashwell G, Morell AG, Stockert RJ. Modulation of the asialoglycoprotein receptor in human hepatoma cells: effect of glucose. Hepatology. 1994 ;19:432-9.
Eichbaum Q, Heney D, Raveh D, Chung M, Davidson M, Epstein J, Ezekowitz RA. Murine macrophage mannose receptor promoter is regulated by the transcription factors PU.1 and SP1. Blood. 1997 90:4135-43.
Weigel PH, Yik JH. Glycans as endocytosis signals: the cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate receptors. Biochim Biophys Acta. 2002 ;1572:341-63.
Stryer, Biochemistry, third edition, W. H. Freeman and Company/ New York, pp. 184-187.
Bujanover et al., The effect of dexamethasone and glucagon on the expression of hepatocyte plasma membrane proteins during development. Hepatology. Jul.-Aug. 1988;8(4):722-7.PubMed 2899049, Abstract.
Zhu et al., Dexamethasone-mediated up-regulation of the mannose receptor improves the delivery of recombinant glucocerebrosidase to Gaucher macrophages. J Pharmacol Exp Ther. Feb. 2004;308(2):705-11. Epub Nov. 10, 2003.
Weinreb et al., Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher RegistryThe American Journal of Medicine, vol. 113, Issue 2, pp. 112-119.
Charrow et al., The Gaucher Registry, demographics and disease, Archives of Internal Medicine 2000, pp. 2835-2843.
Oqueh et al., Antenatal dexamethasone and the growth hormone-insulin-like growth factor axis.Hum Reprod. Jun. 2000 ;15(6):1403-6.
Brieva et al., Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma.Am J Respir Crit Care Med. Jan. 2000;161(1):293-6.
Nelson et al., Oral glucocorticosteroid-sparing effect of budesonide administered by Turbuhaler: a double-blind, placebo-controlled study in adults with moderate-to-severe chronic asthma. Pulmicort Turbuhaler Study Group.Chest. May 1998;113(5):1264-71.
Richard et al., Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase.Blood. Sep. 1, 1993;82(5):1402-9.
Greenspan, Appleton & Lange, 1991, pp. 323-340.
Grabowski GA, et al., Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources.Ann Intern Med. Jan. 1, 1995;122(1):33-9.
Barton NW, et al., Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci U S A. Mar. 1990;87(5):1913-6.
Anderson et al., Individualization of long-term enzyme replacement therapy for Gaucher diseaseGenetics in Medicine:vol. 7(2)Feb. 2005pp. 105-110.
Watson et al. Recombinant DNA, second edition, 2001, pp. 453-455.
Kornfeld, S. and Mellman, I., “The Biogenesis of Lysosomes,”Annual Review Cell Biology, 5:483-525 (1989).
Friedman, B., et al., “A Comparison of the Pharmacological Properties of Carbohydrate Remodeled Recombinant and Placental-Derived β-Glucocerebrosidase: Implications for Clinical Efficacy in Treatment of Gaucher Disease,”Blood, 93(9):2807-2816 (1999).
Clairmont, K.B., and Czech, M.P., “Insulin Injection Increases the Levels of Serum Receptors for Transferrin and Insulin-Like Growth Factor-II/Mannose-6-Phosphate in Intact Rats,”Endocrinology, 127(4):1568-1573 (1990).
Zhou, M., et al., “Insulin-dependent Protein Trafficking in Skeletal Muscle Cells,”American Journal of Physiology(Endocrinology Metabol, 38), 275(2): E187-E196 (1998).
Villevalois-Cam, L., et al.,“Insulin-Induced Redistribution of the Insulin-Like Growth Factor II/Mannose 6-Phosphate Receptor in Intact Rat Liver,”Journal of Cellular Biochemistry, 77:310-322 (2000).
Kandror, K.V. and Pilch, P.F., “The Insulin-like Growth Factor II/Mannose 6-Phosphate Receptor Utilizes the Same Membrane Compartments as GLUT4 for Insulin-dependent Trafficking to and from the Rat Adipocyte Cell Surface,”Journal of Biological Chemistry, 271(36):21703-21708 (1996).
Zhang, Q., et al., “Glucose Increases Both the Plasma Membrane Number and Phosphorylation of Insulin-like Growth Factor II/Mannose 6-Phosphate Receptors,”Journal of Biological Chemistry, 272(38):23703-23706 (1997).
He, X, et al., “Characterization of Human Acid Sphingomyelinase Purified from the Media of Overexpressing Chinese Hamster Ovary Cells,”Biochimica et Biophysica Acta, 1432: 251-264 (1999).
Ceredase Prescribing Information, http://gaucher.mgh.harvard.edu/ceredaseprescribe,1995, Genzyme Corporation, retrieved on Jul. 8, 2003.
Cowan, H.B., et al., “Dexamethasone Up-Regulates Mannose Receptor Activity by Increasing mRNA Levels,”Archives of Biochemistry and Biophysics, 296(1):314-320 (1992).
Stein, M., et al., “Interleukin 4 Potently Enhances Murine Macrophage Mannose Receptor Activity: A Marker of Alternative Immunologic Macrophage Activation,”Journal of Experimental Medicine, 176:287-292 (1992).
Mokoena, T. and Gordon, S., “Human Macrophage Activation,”Journal of Clinical Investigation, 75:624-631 (1985).
Schreiber, S., et al., “Regulation of Mouse Bone Marrow Macrophage Mannose Receptor Expression and Activation by Prostaglandin E and IFN-γ,”The Journal of Immunology, 151(9):4973-4981 (1993).
Treichel, U., et al., “Effects of Cytokines on Synthesis and Function of the Hepatic Asialoglycoprotein Receptor,”Journal of Cellular Physiology, 158:527-534 (1994).
Van Der Ploeg, A.T., et al., “Receptor-Mediated Uptake of Acid α-Glucosidase Corrects Lysosomal Glycogen Storage in Cultured Skeletal Muscle,”Pediatric Research, 24(1): 90-94 (1988).
Van Der Ploeg, A.T., et al., “Intravenous Administration of Phosphorylated Acid α-Glucosidase Leads to Uptake of Enzyme in Heart and Skeletal Muscle of Mice,”Journal of Clinical Investigation, 87: 513-518 (1991).
Zimran, A. et al., “Commentary: Low-Dose High-Frequency Enzyme Replacement Therapy Prevents Fractures Without Complete Suppression of Painful Bone Crises in Patients with Severe Juvenile Onset Type I Gaucher Disease,”BCMD, 24(15): 303-305 (1998).
Cerezyme® (Imiglucerase for injection) product insert, Aug. 27. 1996.
Reuser, A., et al., “Enzyme Therapy for Pompe Disease: from Science to Industrial Enterprise,”European Journal of
Cheng Seng H.
Zhu Yunxiang
Genzyme Corporation
Hamilton Brook Smith & Reynolds P.C.
Leavitt Maria
LandOfFree
Methods of enhancing lysosomal storage disease therapy by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of enhancing lysosomal storage disease therapy by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of enhancing lysosomal storage disease therapy by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4219666